Syntex' Naprosyn
Executive Summary
OTC switch application review by joint meeting of FDA's Arthritis and OTC Drugs Advisory Committees will take place June 1 in FDA's Parklawn building, conference rooms D & E. The committee will also discuss juvenile rheumatoid arthritis guidelines. On June 2, the committee will meet in closed session. The meeting begins at 8:30 a.m. both days.